A Study of Immunological Biomarkers as Predictors of Cardiovascular Events

Status Completed

Clinical Trial Summary

Cardiovascular disease linked to atherosclerosis (e.g. infarcts, cerebro-vascular accidents) are one of the main causes of mortality in the general population. The recruitment of macrophages from the walls of the arterial lumen followed by unregulated capture of oxidated LDL (LDLox) leads to the accumulation of cholesterol esters and the formation of foamy cells characteristic of fatty streaks, the first phase of atherogenesis. These fatty streaks are rarely followed by clinical events, but can progress to complicated atheromatoses (calcification, rupture) resulting in the occurrence of various clinical events such as myocardial infarction and cerebro-vascular accidents (CVA). Once oxidated, LDL becomes immunogenic and induces anti-LDLox antibody production that could be markers of progression of atherosclerosis. During LDL oxidation, a multitude of specific oxidative epitopes (SOE) such as oxidated phospholipids (PLox) and malondialdehyde-lysine epitopes (MDA) are generated. In order to measure the level of markers in the blood, researchers developed a series of immunologic levels in vitro, using specific antibodies directed against well-defined epitopes. Recently, it was shown that Lp(a ) would be the preferred transporter of these PLox. In fact, several clinical studies show a strong correlation between PLox/apoB concentrations and Lp(a). This marker (PLox/apoB) predicts future morbidity and mortality due to cardiovascular diseases, including CVA, up to 15 years in advance, independent of all other known risk factors. CD36 is a scavenger receptor that recognizes LDLox, but more specifically PLox present in these lipoproteins .One soluble form of inflammatory CD36 (sCD36) was recently identified. In this study, only healthy volunteers were recruited in order to be able to establish normal serum ranges of different immunologic biomarkers.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Cardiovascular Abnormalities

Clinical Trial Details

NCT number	NCT02894060
Study type	Interventional
Source	Centre Hospitalier Universitaire, Amiens
Contact
Status	Completed
Phase	N/A
Start date	June 2014
Completion date	June 2016

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT05542238` - The Effect of Acute Exercise on Cardiac Autonomic, Cerebrovascular, and Cognitive Function in Spinal Cord Injury	N/A
Active, not recruiting	`NCT02973126` - Heartflow (AFFECTS)	Phase 3
Withdrawn	`NCT00844935` - Electrocardiographic Autonomic Function Measures in Mechanically Ventilated Patients	N/A
Completed	`NCT01410487` - Effects of Weight Loss on Cardio-respiratory Function	N/A
Withdrawn	`NCT00807274` - Renal Function in Adults With Congenital Heart Disease.	N/A
Withdrawn	`NCT00468702` - Postoperative Canadian Oral Anticoagulation Self-management (Post-COAGS) Trial	N/A
Completed	`NCT04340388` - Contribution of Dolutegravir to Obesity and Cardiovascular Disease	Phase 4
Completed	`NCT03758092` - Cardiovascular Screening in Infants Born Small for Gestational Age
Completed	`NCT03545672` - Early Identification of Myocardial Impairment in PBC
Recruiting	`NCT06091384` - Inspiratory Muscle Strength Training in Post-Covid Syndrome	N/A
Completed	`NCT04586894` - Adverse Myocardial and Vascular Side Effects of Immune Checkpoint Inhibitors
Completed	`NCT03826914` - The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults	N/A
Not yet recruiting	`NCT05624255` - Correlating the Measure of Retinal Vascular Density Through Angio-OCT With Calcium Score	N/A
Completed	`NCT02966028` - Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)	Phase 2
Completed	`NCT01820702` - Short Term Bed Rest Study: Evaluation of the Use of Artificial Gravity, Induced by Short-arm Centrifugation	N/A
Recruiting	`NCT04766203` - Relative Energy Deficiency in Sport Multicenter Study	N/A
Completed	`NCT01811667` - Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations	Phase 3
Terminated	`NCT02351726` - Mitroflow DL Post Approval Study- North America	N/A
Completed	`NCT02616913` - Evaluation of the Cardiac Effects of a Novel Food Ingredient in Healthy Male Subjects	N/A
Completed	`NCT00901394` - Vitamin B12 and Folate Administration on Homocysteine Concentrations After Nitrous Oxide Anesthesia	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study of Immunological Biomarkers as Predictors of Cardiovascular Events — BIOKID

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms